Vor Bio: ASH presentations show trem-cel engraftment; CD33CART 40% complete remission at highest dose

Vor Biopharma Inc.

VBP101 (trem-cel) abstract accepted for oral at ASH; shows robust neutrophil engraftment and hematologic protection from Mylotarg.
CD33CART Phase 1: 2/5 (40%) evaluable patients at DL4 achieved complete remission; 4/19 had CRS ≥ Grade 3.
VCAR33 ALLO uses same CAR-T construct as CD33CART but from healthy donors; VBP301 trial-in-progress poster at ASH.
Preclinical collaboration with Janssen: CD33-deleted allografts synergistic with JNJ-67571244, reducing cytokines.
Single-cell analysis of 28 AML patients (most comprehensive to date) accepted for oral presentation at ASH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.